Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Westermann

Showing results (111-120 of 134) with videos related to

Pageof 14
Sort By:
Nature Communications|February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteomeSabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
Nature Genetics|June 30, 2015
Mutational dynamics between primary and relapse neuroblastomasAlexander Schramm, Johannes Köster, Yassen Assenov, et al.
Cell Reports|July 21, 2021
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerSebastian M Dieter, Christine Siegl, Paula L Codó, et al.
Nature Communications|September 13, 2019
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomesJulian Musa, Florencia Cidre-Aranaz, Marie-Ming Aynaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Prognostic impact of gene expression-based classification for neuroblastomaAndré Oberthuer, Barbara Hero, Frank Berthold, et al.
Nature Communications|November 20, 2018
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targetsBieke Decaesteker, Geertrui Denecker, Christophe Van Neste, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markersAndré Oberthuer, Dilafruz Juraeva, Barbara Hero, et al.
Nature Cancer|April 28, 2022
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosisHamed Alborzinia, Andrés F Flórez, Sina Kreth, et al.
Nature|May 7, 2025
Oncogene aberrations drive medulloblastoma progression, not initiationKonstantin Okonechnikov, Piyush Joshi, Verena Körber, et al.
NPJ Precision Oncology|December 27, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORMHeike Peterziel, Nora Jamaladdin, Dina ElHarouni, et al.
Pageof 14

Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
Nature Communications|February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteomeSabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
Nature Genetics|June 30, 2015
Mutational dynamics between primary and relapse neuroblastomasAlexander Schramm, Johannes Köster, Yassen Assenov, et al.
Cell Reports|July 21, 2021
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerSebastian M Dieter, Christine Siegl, Paula L Codó, et al.
Nature Communications|September 13, 2019
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomesJulian Musa, Florencia Cidre-Aranaz, Marie-Ming Aynaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Prognostic impact of gene expression-based classification for neuroblastomaAndré Oberthuer, Barbara Hero, Frank Berthold, et al.
Nature Communications|November 20, 2018
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targetsBieke Decaesteker, Geertrui Denecker, Christophe Van Neste, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markersAndré Oberthuer, Dilafruz Juraeva, Barbara Hero, et al.
Nature Cancer|April 28, 2022
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosisHamed Alborzinia, Andrés F Flórez, Sina Kreth, et al.
Nature|May 7, 2025
Oncogene aberrations drive medulloblastoma progression, not initiationKonstantin Okonechnikov, Piyush Joshi, Verena Körber, et al.
NPJ Precision Oncology|December 27, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORMHeike Peterziel, Nora Jamaladdin, Dina ElHarouni, et al.
Pageof 14